Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 481 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HER2 Positive Metastatic Breast Cancer Clear all
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Exemestane, Gamma-Secretase Inhibitor RO4929097, Goserelin Acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Tampa, Florida • Atlanta, Georgia • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 24, 2015 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions
Personalis NeXT Personal, Natera Signatera, Trastuzumab deruxtecan-nxki
Diagnostic Test · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer
Interventions
PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
trastuzumab, aldesleukin, laboratory biomarker analysis, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Brain Metastases, HR+ Metastatic Breast Cancer
Interventions
Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Oxaliplatin, Trastuzumab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated May 1, 2011 · Synced May 22, 2026, 4:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Healthy Subject, HER2 Positive Breast Carcinoma, HER2/Neu Negative, Luminal A Breast Carcinoma, Luminal B Breast Carcinoma, Progesterone Receptor Negative, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Aspiration of Breast, Biospecimen Collection
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
40 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
HER-2/neu intracellular domain protein, leukapheresis, laboratory biomarker analysis, sargramostim, immunologic technique, synthetic tumor-associated peptide vaccine therapy
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Tucatinib, Doxil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Columbia, Maryland • Bensalem, Pennsylvania • Nashville, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 22, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Breast Adenocarcinoma, Inflammatory Breast Carcinoma
Interventions
pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
3
States / cities
Duarte, California • Lancaster, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Breast Cancer
Interventions
Taselisib, Placebo, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
16
States / cities
Tucson, Arizona • Atlanta, Georgia • Marietta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab (drug), Herceptin (drug)
Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
18
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumors, Breast Cancer
Interventions
Tanespimycin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Scottsdale, Arizona • Tucson, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
Interventions
Tesevatinib, Trastuzumab
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
La Jolla, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 22, 2026, 4:14 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, Fulvestrant
Drug
Lead sponsor
Nancy Chan, MD
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Lansing, Michigan • Omaha, Nebraska • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced May 22, 2026, 4:14 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07220060, letrozole, abemaciclib, palbociclib, ribociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
218
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 22, 2026, 4:14 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Metastatic Cervical Cancer
Interventions
Almac HER-Seq Assay
Diagnostic Test
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced May 22, 2026, 4:14 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
DiviTum® TKa assay, Study Care Plans
Device · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
ribociclib (LEE011), Exemestane, Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced May 22, 2026, 4:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions
BKM120, Trastuzumab, Capecitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
87
States / cities
Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced May 22, 2026, 4:14 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 22, 2026, 4:14 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
Gedatolisib, Palbociclib, Letrozole, Fulvestrant
Drug
Lead sponsor
Celcuity Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced May 22, 2026, 4:14 AM EDT